China Health Group Ltd (HK:0673)
:0673
Top Page
China Health Group
(0673)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$0.50
▼(-34.61% Downside)
Action:ReiteratedDate:03/24/26
The score is held down primarily by very weak financial performance (multi-year revenue declines, sharply widening losses, and renewed cash burn alongside negative equity). Technical indicators also point to a soft trend with bearish momentum, while valuation offers limited support due to loss-making results and no provided dividend yield.
Positive Factors
Integrated healthcare services
A diversified healthcare model spanning hospital investments, management and healthcare technology creates multiple durable revenue channels. This structural breadth supports cross-selling, operational synergies and the potential to reallocate resources as projects mature, reducing single-source dependence.
Negative Factors
Multi-year revenue decline
Sustained top-line contraction erodes scale, reduces bargaining power and worsens fixed-cost absorption. Continued revenue decline undermines margin recovery efforts, increases per-unit costs, and lengthens the timeline and difficulty of returning to positive operating leverage without structural changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated healthcare services
A diversified healthcare model spanning hospital investments, management and healthcare technology creates multiple durable revenue channels. This structural breadth supports cross-selling, operational synergies and the potential to reallocate resources as projects mature, reducing single-source dependence.
Read all positive factors
China Health Group (0673) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$721.31M
Dividend YieldN/A
Average Volume (3M)617.89K
Price to Earnings (P/E)―
Beta (1Y)0.21
Revenue Growth-17.39%
EPS Growth-45.76%
CountryHK
Employees118
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,387,138,200
10 Day Avg. Volume474,015
30 Day Avg. Volume617,889
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-14.98
Price to Sales (P/S)2.95
P/FCF Ratio-13.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China Health Group Business Overview & Revenue Model
Company Description
China Health Group (0673) is a healthcare-focused company operating primarily in China. The company is engaged in various sectors including pharmaceuticals, health supplements, and medical services. It aims to improve health outcomes through the p...
How the Company Makes Money
China Health Group generates revenue primarily through the management and operation of healthcare facilities, including hospitals and medical institutions, which generate income from patient services, medical procedures, and related healthcare off...
China Health Group Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
27
Negative
Cash Flow
22
Negative
| Breakdown | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 38.94M | 59.93M | 76.41M | 107.03M | 87.89M |
| Gross Profit | 9.23M | 13.64M | 27.19M | 28.69M | 25.99M |
| EBITDA | -63.71M | -37.42M | -33.04M | -4.38M | -1.47M |
| Net Income | -67.79M | -40.19M | -42.05M | -12.21M | -7.74M |
Balance Sheet | |||||
| Total Assets | 147.35M | 192.32M | 221.19M | 225.96M | 217.82M |
| Cash, Cash Equivalents and Short-Term Investments | 1.05M | 4.01M | 11.48M | 8.54M | 4.59M |
| Total Debt | 6.50M | 5.66M | 6.04M | 18.47M | 5.36M |
| Total Liabilities | 147.25M | 132.56M | 127.23M | 140.82M | 117.83M |
| Stockholders Equity | -7.66M | 52.04M | 86.33M | 79.58M | 95.04M |
Cash Flow | |||||
| Free Cash Flow | -8.35M | -7.03M | -9.59M | 31.00M | -10.90M |
| Operating Cash Flow | -6.76M | -6.40M | -8.22M | 31.80M | -9.06M |
| Investing Cash Flow | -1.58M | -301.00K | -5.40M | -35.29M | -1.84M |
| Financing Cash Flow | 8.79M | -1.24M | 27.66M | 12.96M | 2.63M |
China Health Group Technical Analysis
Negative
0.76
Price Trends
0.62
Negative
0.67
Negative
0.55
Negative
Market Momentum
-0.03
Positive
35.06
Neutral
33.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0673, the sentiment is Negative. The current price of 0.76 is above the 20-day moving average (MA) of 0.57, above the 50-day MA of 0.62, and above the 200-day MA of 0.55, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 35.06 is Neutral, neither overbought nor oversold. The STOCH value of 33.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0673.
China Health Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$6.36B | 19.61 | 6.83% | 2.72% | 29.81% | 10.40% | |
70 Outperform | HK$65.28B | 3.75 | 8.62% | 3.75% | -2.68% | -21.45% | |
67 Neutral | HK$65.93B | ― | 7.64% | 2.67% | 2.77% | 39.24% | |
66 Neutral | HK$1.82B | 20.84 | 4.85% | 3.81% | 0.33% | -44.28% | |
60 Neutral | HK$627.48M | 7.99 | 7.98% | 8.03% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$721.31M | -5.63 | 476.63% | ― | -17.39% | -45.76% |
* Healthcare Sector Average
HK:0673
China Health Group
0.52
0.33
173.68%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.94
1.09
10.10%
HK:1099
Sinopharm Group Co
20.92
3.09
17.36%
HK:1931
IVD Medical Holding Limited
1.12
-0.58
-34.12%
HK:2192
Medlive Technology Co., Ltd.
8.61
-4.12
-32.36%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.81
-1.49
-20.41%
China Health Group Corporate Events
China Health Group Raises HK$25.27 Million Through New Share Subscription
Feb 26, 2026
China Health Group Limited has completed a share subscription, issuing 48 million new shares at HK$0.53 each under a general mandate, expanding its share capital by about 3.6 percent. The new shares represent roughly 3.46 percent of the enlarged c...
China Health Group Cancels 40.6 Million Share Options, Keeps Future Grant Capacity Intact
Feb 13, 2026
China Health Group Limited has cancelled in full the 40,638,000 share options it granted on 2 February 2026 to 11 grantees, exercising the board’s discretion under its share option scheme after none of the options had been validly exercised....
China Health Group Grants Share Options Equal to 3.03% of Share Capital
Feb 2, 2026
China Health Group Limited has granted 40,638,000 share options, equivalent to about 3.03% of its issued share capital, to 11 directors and employees under its share option scheme adopted in September 2023. The options, exercisable at HK$0.66 per ...
China Health Group to Raise HK$25 Million via 48 Million-Share Subscription
Feb 2, 2026
China Health Group Limited has entered into a subscription agreement with an independent Hong Kong investment holding company to issue 48 million new shares under its existing general mandate at HK$0.53 per share. The new shares will represent abo...
China Health Group Details Funding Moves to Address Going-Concern Disclaimer
Jan 23, 2026
China Health Group Limited has provided an update on measures to address its auditors’ disclaimer of opinion on the company’s ability to continue as a going concern for the year ended 31 March 2025. The company has completed share subs...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.